Introduction 4 To whom correspondence should be addressed Antiprogestins, as exemplified by mifepristone, have broad therapeutic potential in the treatment of conditions such as The overall aim of these studies was to investigate the cervical ripening, induction of labour, endometriosis and oral and i.m. bioavailability of CDB-2914 in intact female uterine fibroids, as well as use as contraceptive agents (Spitz rhesus monkeys, and to compare the serum concentrations and Bardin, 1993) . The antiprogestin CDB-2914 (17α-acetoxyof CDB-2914 with that of mifepristone following oral [11β-(4-N,N-dimethylaminophenyl) ]-19-norpregna-4,9-dieneadministration. In the first study, a 50 mg bolus of 3,20-dione) is structurally related to mifepristone, but possesses CDB-2914 per monkey was administered intravenously, 17β-acetyl and 17α-acetoxy groups instead of 17β-hydroxy orally or intramuscularly. The area under the serum and 17α-propynyl groups ( Figure 1 ). Thus, CDB-2914 may concentration-time curve for 72 h (AUC 0-72 ) following i.v.
be considered a derivative of 19-norprogesterone, whereas injection was 18 320 ⍨ 2718 ng/ml•h, and that for oral mifepristone is derived from 19-nortestosterone. CDB-2914 is administration was 10 464 ⍨ 3248 ng/ml•h. Thus, the also known variously as RTI 3021-12 (Cook et al., 1994) , RU oral bioavailability of CDB-2914 equivalents was 56%.
44675 (Teutsch and Philibert, 1994) and HRP 2000 (Tarantal The AUC 0-168 h following i.m. injection was 11 226 ⍨ et al., 1996) . CDB-2914, like mifepristone and other 11β-1130 ng/ml•h. Therefore, the i.m. bioavailability of CDBaryl substituted antiprogestins, binds to progesterone and 2914 equivalents was 62%. In the second study, the serum glucocorticoid receptors (PR, GR) with high affinity (Cook concentrations of CDB-2914 and mifepristone equivalents et al., 1994; Hild-Petito et al., 1996) . In the rat, CDB-2914 were compared following an oral bolus dose in two different had an oral anti-ovulatory potency 8-fold greater than that of formulations. When administered at 5 mg/kg in aqueous mifepristone (Reel et al., 1998) . Further evaluation in classical suspending vehicle (ASV), the mean peak serum concentraantiprogestational bioassays in the rabbit indicated that CDBtion (C max ) of CDB-2914 equivalents (192 ⍨ 64 ng/ml) 2914 was about equipotent to mifepristone when administered occurred at 5 ⍨ 1 h, whereas the C max of mifepristone subcutaneously, but two to three times more potent than equivalents (82 ⍨ 25 ng/ml) occurred at 3 ⍨ 1 h. Following mifepristone when administered orally (Cook et al., 1994) . administration in gelatin capsules (35 mg/monkey), the Thus, it appeared that differences in serum concentrations C max of CDB-2914 equivalents (129 ⍨ 24 ng/ml) occurred between CDB-2914 and mifepristone following oral adminisat 5 ⍨ 1 h, while the C max of mifepristone equivalents tration might account for the differences in oral biological (31 ⍨ 8 ng/ml) occurred at 3 ⍨ 1 h. The serum conpotencies.
centration (AUC 0-120 h ) of CDB-2914 equivalents was
The pharmacokinetics of mifepristone, the most widely 4.7-or 5.3-fold greater than that of mifepristone equivalents characterized 11β-aryl substituted antiprogestin, have been when administered orally in ASV or gelatin capsules studied mostly in women following oral administration, respectively. The serum protein binding characteristics of although some studies have been conducted in monkeys CDB-2914 were also studied. CDB-2914 bound to human and rats (Deraedt et al., 1985; Lähteenmäki et al., 1987 ; α 1 -acid glycoprotein (AAG), but not with as high an Heikinheimo et al., 1994) . Following oral administration in affinity as mifepristone. In contrast, neither CDB-2914 nor humans, mifepristone is characterized by rapid absorption, mifepristone bound with high affinity to AAG, corticowith peak serum concentrations occurring in 1-2 h and a long steroid binding globulin or sex hormone binding globulin half-life of 25-30 h (Heikinheimo, 1997) . The serum profiles in monkey serum. Collectively, these results indicated that of three of the known metabolites of mifepristone, the mono-CDB-2914 was more efficiently absorbed than mifepristone and didemethylated and hydroxylated forms, show the same following oral administration to female rhesus monkeys.
pattern of disappearance from the circulation as the parent steroid. In addition, the monodemethylated and hydroxylated metabolites bind to human uterine PR and placental GR the rat, absorption was also rapid; however, in contrast to Materials and methods humans, the elimination half-lives were 15 h and 1-2 h
Steroids and vehicles
respectively (Deraedt et al., 1985; Heikinheimo et al., 1994) .
The chemical structures for CDB-2914, mifepristone and progesterone
The most likely explanation for the differences among the are shown in Figure 1 . CDB-2914 (17α-acetoxy-[11β-(4-N,N- three species appears to be the lack of a high-affinity mifepridimethylaminophenyl)]-19-norpregna-4,9-diene-3,20-dione), the 3-stone binding protein in monkey and rat sera (Moguilewsky carboxymethyloxime-bovine serum albumin (BSA) conjugate of and Philibert, 1985; Heikinheimo et al., 1994) . In humans, α 1 -CDB-2914 and the 3-carboxymethyloxime-histamine conjugates of acid glycoprotein (AAG) has been identified as the highboth CDB-2914 and mifepristone (11β[4-N,N-dimethylaminophenyl] ,17β-hydroxy,17α-propynyl estra-4,9-dien-3-one) were synaffinity binding protein for mifepristone (Grimaldi et al., 1992) . (Heikinheimo et al., 1987b; Grimaldi et al., 1992 (Westphal, 1986; Juchem Israel) . The mono-and didemethylated and hydroxylated metabolites and Pollow, 1990; Fotherby, 1995 using a modified chloramine-T method (Niswender et al., 1975) and purified twice by HPLC using a 5 µm LiChrosorb RP-18 column (4.6ϫ250 mm; Merck, Darmstadt, Germany) and a gradient of acetonitrile:water (40:60) to 100% acetonitrile over 40 min at a flow hydroxylated metabolite of CDB-2914 exhibited Ͻ1% crossrate of 1 ml/min. reactivity.
Animals Radioimmunoassay Nine intact, regular cycling, female rhesus monkeys (Macaca mulatta)
Radioimmunoassay data were analysed using a four-parameter sigof mean (Ϯ SE) bodyweight 7.6 Ϯ 0.5 kg were used in these studies.
moidal computer program (RiaSmart™ Data Reduction Program, Menstrual cycles were monitored daily by vaginal swabs to detect Packard Instrument Co., Meriden, CT, USA). Quality control parathe presence and quantity of blood. Male New Zealand White rabbits meters including percentage specific bound (B 0 ), percentage nonweighing 3-4 kg were employed for antisera production. Animals specific bound (NSB), EC 20 , EC 50 and EC 80 intercepts, slope and were maintained in facilities accredited by the Association for correlation coefficient were calculated routinely by the program for Assessment and Accreditation of Laboratory Animal Care Interall standard curves. The usable range of the CDB-2914 standard national, and the environmental conditions of the animal rooms were curve was 1 to 400 pg/tube, with a mean (Ϯ SE) mid-point of maintained as recommended by the National Research Council 30 Ϯ 2 pg/tube (n ϭ 10) and a mean slope of -0.91 Ϯ 0.03 (n ϭ 10). (National Research Council, 1996) to the maximum extent possible.
The average limit of detection was 1 Ϯ 0.1 pg/tube. The recovery of The Institutional Animal Care and Use Committee of BIOQUAL CDB-2914 from low-, mid-and high-concentration quality control approved all study protocols. serum pools run with each assay averaged 100 Ϯ 8% (n ϭ 3). The interThe same three to four monkeys were used for both CDB-2914 and intra-assay coefficients of variation were 7% and 7% for CDBand mifepristone pharmacokinetic studies. The monkeys were not 2914, and 9% and 18% for mifepristone respectively. anaesthetized during dosing or blood collection. The animals were Serum samples from five monkeys dosed orally with 5 mg CDBheld in a chair restraint during oral and i.v. dosing, and for an 2914/kg were assayed for CDB-2914 and its putative immunoreactive additional hour after dosing. In the i.v. study, monkeys were injected metabolites over a series of dilutions. Using a semi-log plot of percent at random times in their menstrual cycles. In all other studies, the bound versus concentration, the diluted serum samples decreased in monkeys were dosed at midcycle (days 13-16; day 1 ϭ first day of a linear and parallel fashion to the CDB-2914 standard curve. menses) and fasted overnight before dosing and for 4 h after oral Parallelism was assessed by comparison of the mean slopes calculated dosing, which was performed via a gastric catheter. When test by RiaSmart™ for the regression lines (Altman, 1991) . The mean compounds were administered as aqueous suspensions the catheter slope of the standard curves (n ϭ 6) was -0.86 [95% confidence was flushed with additional vehicle to ensure complete delivery. intervals (CI) -0.76 to -0.96], and the mean slope of the diluted Gelatin capsules containing test compounds were forced through the serum samples (n ϭ 5) was -0.80 (95% CI -0.66 to -0.94). catheter using a bolus of air. Blood samples were collected by
The study serum samples were assayed for CDB-2914 or mifeprivenepuncture from the cephalic, saphenous or femoral veins immedistone equivalents as follows. CDB-2914 and mifepristone equivalents ately before and at various times after dosing. Serum was obtained were extracted from sera with absolute methanol (1:4, v/v). Following by centrifugation at 2600 g for 15 min, and stored at -20°C until centrifugation to remove the protein precipitate, the supernatant assayed for CDB-2914 or mifepristone and their immunoreactive extracts were diluted to 20% methanol with assay buffer (50 mmol/l metabolites.
phosphate, pH 7.2, containing 0.1% gelatin), and then diluted further as required with assay buffer containing 20% methanol. Duplicate Antisera 200 µl aliquots were incubated overnight with 30 000 counts per min (c.p.m.) [ 125 I]CDB-2914 or [ 125 I]mifepristone and the respective Polyclonal antisera against CDB-2914 3-carboxymethyloxime-BSA were raised in four male rabbits using a previously described method antibody at 2-6°C. The final methanol concentration in the incubation mixture was 5%. Bound and free radioligand were separated using (Vaitukaitis et al., 1971) . Initially, each rabbit was immunized with divided intradermal injections of 4 mg of the immunogen emulsified a dextran-coated charcoal method (Reel et al., 1979) . Following precipitation of the charcoal by centrifugation (2600 g, 15 min), the in Freund's complete adjuvant:saline (1:1, v/v). This was followed by booster immunizations in Freund's incomplete adjuvant:saline supernatants were decanted and counted for 2 min each in a Packard Cobra™ II gamma counter. The serum equivalents for CDB-2914 or (1:1, v/v) at 4-week intervals until no further increases in antibody titres were obtained. Sera from bleeds nos. 3-5 from the rabbit mifepristone were derived by correcting for aliquot volume and serum dilution factor. Two of the early metabolites of mifepristone in (#67192) with the highest antibody titre and the greatest CDB-2914 specificity were pooled and used for assay development and validation.
women, the N-mono-and -didemethylated products (Deraedt et al., 1985; Heikinheimo et al., 1987a) , cross-reacted with the antibody at This antiserum was titrated with each new preparation of [ 125 I]CDB-2914 to determine the final dilution that resulted in 30-40% specifically 86% and 57% respectively (Table I ). It seems likely that these two metabolites were also produced in female monkeys, though no bound radioligand. The N-mono-and -didemethylated putative metabolites of CDB-2914 exhibited 76% and 59% cross-reactivity with attempt was made at their isolation and identification. The serum concentrations were expressed as ng equivalents of CDB-2914 and the antiserum respectively (Table I) . Progesterone, mifepristone, oestradiol, oestrone, cortisol, testosterone and the putative 17α-mifepristone per ml in order to reflect the unknown contribution of their proximal metabolites which have been found to cross-react with the antisera used.
Serum protein binding
The relative binding affinities (RBA) of SHBG and CBG for CDB-2914, mifepristone, progesterone, oestradiol (SHBG only) and dexamethasone (CBG only) were determined using a published method (Hammond and Lähteenmäki, 1983) . Briefly, aliquots of pooled human serum and pooled female rhesus monkey serum were charcoalstripped and incubated with 5 nmol/l [ 3 H]5α-dihydrotestosterone (5α-DHT) or 5 nmol/l [ 3 H]cortisol and reference standard or competitor concentrations from 1 to 800 nmol/l. Non-specific binding was measured in the presence of a 200-fold molar excess of unlabelled 5α-DHT or cortisol in the SHBG and CBG assays respectively. The SHBG assay also contained 120 nmol/l cortisol to block binding of the competitors to serum CBG. Samples were incubated for 2 h at 4°C. Bound and free radioligands were separated using a dextrancoated charcoal method (Reel et al., 1979) . Following precipitation of the charcoal by centrifugation at 2000 g for 20 min, the supernatants were decanted and counted. The EC 50 values for the 5α-DHT and cortisol standard curves and the competitor curves were calculated using RiaSmart™. The RBA (%) of the competitors were calculated using the following equation: (EC 50 of standard Ϭ EC 50 of competitor)ϫ100. Equilibrium dialysis was used to assess the binding by other serum proteins. Aliquots of female monkey serum diluted 1:100 in phosphate-buffered saline (PBS) (10 mmol/l NaHPO 4 , 144 mmol/l NaCl, pH 7.2) containing 5% ethanol (PBS/5% ethanol) and 12.2 µmol/l purified human AAG (in PBS/5% ethanol) were dialysed against 5 nmol/l [ 3 H]CDB-2914 or 5 nmol/l [ 3 H]mifepristone. Incubations were carried out at 37°C, and both dialysis chambers were sampled over time until equilibrium was reached. At equilibrium (8 h), the percent bound radioligand was calculated using the following . The PROPHET 'drugmodel' procedure was used to determine CDB-2914 was 516 ng/ml, and the mean time to C max was the mean peak serum concentration (C max ; ng/ml) and time to C max 5 h (Table II) . and 24 h after administration ( Figure 2C ). The mean C max for Graphs were prepared using Sigma Plot, version 4.0 (Jandel Scientific).
three monkeys following i.m. injection of 50 mg CDB-2914 was 234 ng/ml, and the mean time to C max was 13 h (Table II) .
In order to make estimates of bioavailability, the mean AUC Results were calculated for circulating concentrations of CDB-2914 Circulating concentrations of CDB-2914 equivalents after equivalents following i.v., oral and i.m. administration (Table  i. 100 gave an oral bioavailability of 56% (Table II) . In comparequivalents varied depending on the route of administration.
ison, the ratio of the i.m. AUC 0-168 h to the i.v. AUC 0-72 h ϫ As expected, serum concentrations of CDB-2914 equivalents 100 yielded an i.m. bioavailability of 62% (Table II) . were highest immediately after a 50 mg bolus i.v. injection in Circulating concentrations of CDB-2914 and mifepristone 70% ethanol/bacteriostatic water and declined exponentially equivalents after oral administration in aqueous suspending thereafter over the 72 h sampling period (Figure 2A) . vehicle (ASV) or gelatin capsules In contrast, oral administration of 50 mg of CDB-2914 in the same vehicle resulted in gradual absorption from the The oral pharmacokinetics of mifepristone have been studied gastrointestinal tract. CDB-2914 equivalents reached C max (239 extensively in women. Therefore, the results of a comparative study of CDB-2914 and mifepristone in female rhesus monkeys to 761 ng/ml) at between 4 and 8 h after dosing, and decreased a Values are mean Ϯ SE (n ϭ 3). b AUC 0-72 h for i.v. and oral; AUC 0-168 h for i.m. As the uptake (or absorption) and clearance of CDB-2914 was expected to be more rapid by the i.v. and oral routes than by the i.m. route, a longer AUC interval was employed for the latter route. c BA ϭ bioavailability; AUC oral or AUC i.m. /AUC i.v. ϫ100. d Arbitrarily assigned. AUC ϭ area under the curve; C max ϭ mean peak serum concentration. Table III ). Although C max and time to C max were not significantly different between the two groups, the AUC 0-120 h for CDB-2914 was significantly greater (P Ͻ 0.05) than that for mifepristone. Hence, the AUC 0-120 h ratio of CDB-2914 was 4.7-fold greater than that of mifepristone (Table III) . Oral administration of 35 mg CDB-2914 in a gelatin capsule yielded a mean C max of 129 ng/ml, and a time to C max of 5 h, whereas 35 mg of mifepristone in a gelatin capsule gave a serum C max of 31 ng/ml and a time to C max of 3 h ( Figure 3B , Table III ). In this instance, C max and time to C max were significantly greater (P Ͻ 0.05) for CDB-2914 than for mifepristone. As observed for the ASV formulation, the AUC 0-120 was significantly greater (P Ͻ 0.05) for CDB-2914 than mifepristone following oral administration in a gelatin capsule. Indeed, the ratio of the CDB-2914 AUC 0-120 h to the mifepristone AUC 0-120 h was 5.3 (Table III) .
Neither CDB-2914 nor mifepristone bound to monkey or human SHBG or CBG. The protein binding assays for each species were performed on two separate occasions. The RBA values of SHBG for oestradiol, which served as a positive control, were 10 Ϯ 1% and 3 Ϯ 1% (mean Ϯ SD, n ϭ 2) for monkey and human respectively. The negative control, progesterone, did not compete with [ 3 H]5α-DHT for binding to either the monkey or human SHBG. For CBG, the mean RBA values for progesterone, the positive control, were 40 Ϯ 6% and 10 Ϯ 3% (mean Ϯ SD, n ϭ 2), for monkey and human respectively. As expected, dexamethasone did not respectively. In addition, there was no evidence of specific binding of either antiprogestin by charcoal-stripped 75-fold might provide some insight into what doses of CDB-2914 diluted monkey serum using the same dextran-coated charcoal would be appropriate for phase I clinical trials pursuant to the method as was employed to assess binding by SHBG and CBG. treatment of endometriosis and uterine fibroids (Passaro et al., 1997) . Oral administration of 5 mg CDB-2914/kg in ASV Discussion resulted in a mean C max of 192 mg/ml, and a mean time to C max of 5 h, whereas 5 mg mifepristone/kg in ASV gave a This study is the first to determine the circulating concentrations and bioavailability of the antiprogestin, CDB-2914. Interesserum C max of 82 ng/ml and a time to C max of 3 h ( Figure 3A , a Values are mean Ϯ SE (n ϭ 3-4). b AUC 0-120 h ratio ϭ AUC 0-120 h CDB-2914/AUC 0-120 h mifepristone. As CDB-2914 and/or its immunoreactive metabolites were still detectable in serum at 72 h (in study no. 1) following i.v. and oral administration, the AUC interval was extended to 0-120 h in this study involving oral administration of CDB-2914 and mifepristone. *Significantly different (P Ͻ 0.05) from mifepristone (Student's t-test). **Significantly different (P Ͻ 0.05) from mifepristone (Student's t-test using log 10 data transformation to achieve normally distributed values and homogeneity of variance).
tingly, oral administration of 5 mg CDB-2914 or mifepristone/ 1994), and this was also observed in female rhesus monkeys in the present study. In contrast, results from the earlier of kg in ASV, or 35 mg per gelatin capsule per monkey resulted in 5-fold higher serum concentrations of CDB-2914 than these studies (Deraedt et al., 1985) described slow and irregular absorption of mifepristone in the cynomolgus monkey. Howmifepristone. The serum concentration of both CDB-2914 and mifepristone and their respective immunoreactive metabolites ever, a different vehicle [polyethylene glycol (PEG) 300] was employed in this study, and this may account for the difference were influenced by the formulation and the route of administration. It also was noteworthy that CDB-2914, whether adminisseen between rhesus and cynomolgus monkeys. In contrast, the absorption of CDB-2914 was slower than mifepristone tered orally or intramuscularly, was characterized by slow absorption and prolonged elimination. The relatively high following administration in either gelatin capsules or in an ASV, as indicated by the time to C max . The difference in bioavailability of CDB-2914 was accompanied by the persistence of detectable concentrations of CDB-2914 and/or its absorption of the two antiprogestins given in these two formulations may reflect the solubility and the extent of immunoreactive metabolites, and this may reflect enterohepatic recirculation as well as the progressive production and recircuaggregation of drug particles in the gastrointestinal tract. The AUC 0-120 h values for CDB-2914 and mifepristone administered lation of proximal CDB-2914 metabolites. In-vivo studies in the human and rat have demonstrated that enterohepatic orally in gelatin capsules were only 67% and 38% respectively that of the AUC values when these drugs were given in ASV. recirculation of mifepristone and its metabolites occurs following oral administration (Heikinheimo et al., 1989 (Heikinheimo et al., , 1994 . In Interestingly, the oral bioavailability of mifepristone ranged from 15% in cynomolgus monkeys to 40% in humans and rats addition, adipose tissue serves as a potential reservoir for mifepristone and the monodemethylated and didemethylated when administered in PEG 300 (monkeys), tablets (humans) and methylacetamide (rats) respectively (Deraedt et al., 1985) . metabolites in both species (Heikinheimo et al., 1989 (Heikinheimo et al., , 1994 , and this may well be the case for CDB-2914 and its proximal
In addition, when the AUC for CDB-2914 in ASV or gelatin capsule were compared with the AUC for mifepristone in ASV metabolites. The re-entry and redistribution of CDB-2914 and its early metabolites into the vasculature may partially account or gelatin capsule, the serum concentrations of CDB-2914 were 4.7-and 5.3-fold greater than those of mifepristone. for the sustained serum concentrations of CDB-2914 equivalents seen in this study, regardless of the route of administration.
Hence, CDB-2914 appeared to be more efficiently absorbed than did mifepristone in the rhesus monkey, regardless of the Although the metabolites of CDB-2914 were not isolated and characterized in the present study, it appears likely that oral dosing formulation. The persistence of detectable concentrations of CDB-2914 two of the earliest metabolites would be the monodemethylated and didemethylated products, based on an analogy to mifepriand its immunoreactive metabolites in serum following oral administration of CDB-2914 in ASV or gelatin capsules, or stone (Heikinheimo et al., 1989 (Heikinheimo et al., , 1994 . Noteworthy, the proximal metabolites of mifepristone were biologically active by i.m. injection, suggests significant extravasation of CDB-2914 and its putative immunoreactive metabolites. It is also to varying degrees in the rat (Deraedt et al., 1985) . The monodemethylated and didemethylated derivatives of CDBpossible that the profile of metabolites is different following oral administration as compared with i.m. injection. Early 2914 have been chemically synthesized and tested. The synthetic monodemethylated metabolite of CDB-2914 exhibited studies on the pharmacokinetics and metabolism of mifepristone indicated that, due to first-pass metabolism, the volume considerable affinity for the rabbit uterine PR and thymic GR, as well as antiprogestational, anti-ovulatory and postcoital of distribution in humans was only 10% of body weight, whereas in rats and cynomolgus monkeys the volume of antifertility activity in the rat (unpublished data).
The absorption of orally dosed mifepristone has been shown distribution represented 135% and 200% respectively of body weight (Deraedt et al., 1985) . Of note was the finding that if the to be rapid in humans (Lähteenmäki et al., 1987; Kekkonen et al., 1996) and rats (Deraedt et al., 1985; Heikinheimo et al., elimination half-life for mifepristone and its immunoreactive
